anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 46,231-46,260
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

46,231-46,260 of 110,355

filter-aware
67
The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
68
The slide uses a 'fraud-exposure' narrative, highlighting a specific omission in a scientific paper to imply corporate malfeasance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
70
The slide uses a 'villain' framing by highlighting the industry-wide failure of a specific drug class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
74
The slide uses a combination of narrative summary and a direct excerpt from a scientific review paper to validate the difficulty of the target.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
75
The slide uses a 'before-after' narrative structure to show that shifting chemical scaffolds did not solve the underlying safety issues in H3 receptor drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
76
The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
77
The slide uses a 'villain critique' approach by leveraging a peer's own research to undermine the target's (Bioprojet/pitolisant) technology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
79
The slide uses a forensic literature review approach to highlight historical concerns about the drug's safety profile (cardiotoxicity, bioavailability, etc.) that were allegedly ignored or suppressed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
80
The slide uses a primary text block to summarize the contradiction, followed by a direct excerpt from a 2008 paper as evidence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
81
The slide uses a direct quote from a scientific paper to undermine the viability of the drug candidate mentioned in the lower text block.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
82
The slide uses a 'villain critique' style to undermine the target drug (pitolisant) by associating it with failed industry-wide efforts.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
83
The slide uses a Q&A format to present expert testimony as evidence of product failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
84
The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
85
The slide uses a Q&A format to build a case against the drug's efficacy based on metabolic pathways.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
87
The slide uses a Q&A transcript format to validate the thesis that the drug class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
88
Uses expert quotes to establish a 'villain' (the drug class/mechanism) and preemptively rebut its efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
92
The slide uses a Q&A transcript format to highlight a specific failure case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
93
The slide uses a Q&A format to build a case against the safety of a drug program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
94
The slide uses a Q&A transcript format to corroborate previous claims about drug instability and poor blood-brain barrier penetration.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
95
The slide uses expert testimony to establish a precedent of failure in the H3 receptor space, specifically contrasting J&J's robust trials with Bioprojet's pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
96
The slide uses a Q&A format to discredit the competitor's R&D rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
97
The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
98
The slide uses direct quotes from a J&J scientist to undermine the credibility of Bioprojet's research capabilities.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
99
The slide uses a combination of summary bullet points and direct quotes from a consultation call to discredit the competitor's scientific rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
100
The slide uses highlighted text to emphasize key quotes from expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit